开盘$14.53
昨收$14.63
当日区间$14.39 – $15.65
成交量42.12M
市值$15.81B
市盈率（TTM）18.0
股息率0.13%
CDE 相关新闻
匹配 Coeur Mining 或代码 CDE 的头条新闻，按最新排序。
- Tianyu Co., Ltd.: Announcement Regarding the Approval of Its Wholly-Owned Subsidiary's Active Pharmaceutical Ingredient by the CDE Review 正面
- The Center for Drug Evaluation (CDE) has accepted Roche's (RHHBY.US) marketing application for faricimab injection, indicated for the treatment of uveitic macular edema.
- Scotiabank Maintains Coeur Mining(CDE.US) With Buy Rating, Maintains Target Price $26.5
- The product of Guobang Pharma's (605507.SH) subsidiary, glyceryl dicaprylate/dicaprate, has passed the joint review and approval process with the finished dosage form by the Center for Drug Evaluation (CDE). 正面
- Guobang Pharma: Glyceryl Dicocoate, a product of its wholly-owned subsidiary, has passed the joint review and approval process with the finished dosage form by the Center for Drug Evaluation (CDE). 正面
- A Quick Look at Today's Ratings for Coeur Mining(CDE.US), With a Forecast Between $18 to $26.5
- ATB Cormark Capital Markets Downgrades Coeur Mining(CDE.US) to Hold Rating, Cuts Target Price to $18 负面
- BMO Capital Maintains Coeur Mining(CDE.US) With Buy Rating, Cuts Target Price to $26 负面
- RBC Capital Maintains Coeur Mining(CDE.US) With Buy Rating, Maintains Target Price $23
- Scotiabank Initiates Coeur Mining(CDE.US) With Buy Rating, Announces Target Price $28.5
- Roth MKM Maintains Coeur Mining(CDE.US) With Buy Rating, Cuts Target Price to $21 负面
- Scotiabank Maintains Coeur Mining(CDE.US) With Buy Rating, Raises Target Price to $28.5 正面
- Tianyu Co., Ltd.: Announcement Regarding the Approval of the Company\'s Active Pharmaceutical Ingredient by the CDE Review 正面
- RBC Capital Maintains Coeur Mining(CDE.US) With Buy Rating, Cuts Target Price to $23 负面
- Tianyu Co., Ltd.: Announcement Regarding the Approval of the Company\'s Active Pharmaceutical Ingredient by the CDE Review 正面
暂无评论——快来第一个聊聊 CDE。
登录后参与讨论。